Bicycle Therapeutics (BCYC) News Today $8.64 -0.04 (-0.40%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.3% - Time to Buy?Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.3% - Here's WhyApril 24 at 1:59 PM | marketbeat.comBicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This DiscountedApril 22 at 4:00 AM | seekingalpha.comNan Fung Group Holdings Ltd Acquires 37,358 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Nan Fung Group Holdings Ltd raised its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 118.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,943 shares of the company's stock after acquirApril 21 at 7:58 AM | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of "Moderate Buy" from BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buyApril 21 at 2:34 AM | marketbeat.comAltium Capital Management LLC Cuts Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Altium Capital Management LLC lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 52.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,352 shares of the company's stApril 20, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Still a Buy?Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's WhyApril 17, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.com1BCYC : Analyst Expectations For Bicycle Therapeutics's FutureApril 9, 2025 | benzinga.comSpringhill Fund Asset Management HK Co Ltd Takes $1.63 Million Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Springhill Fund Asset Management HK Co Ltd purchased a new position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 116,400 shares of the cApril 8, 2025 | marketbeat.comInsider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells 2,237 Shares of StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 2,237 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $8.02, for a total value of $17,940.74. Following the sale, the chief executive officer now directly owns 489,697 shares in the company, valued at $3,927,369.94. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.April 6, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $17,940.74 in StockApril 5, 2025 | insidertrades.comBicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | finance.yahoo.comBicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - Should You Sell?Bicycle Therapeutics (NASDAQ:BCYC) Sets New 1-Year Low - Time to Sell?April 1, 2025 | marketbeat.comBicycle Therapeutics plc: Bicycle Therapeutics Announces New Board and Key Clinical Leadership AppointmentsMarch 29, 2025 | finanznachrichten.deBicycle names Pierre Legault chairman, Eric Westin chief medical officerMarch 29, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Time to Buy?March 28, 2025 | marketbeat.comBicycle Therapeutics Announces New Board and Key Clinical Leadership AppointmentsMarch 27, 2025 | finance.yahoo.comEntryPoint Capital LLC Invests $614,000 in Bicycle Therapeutics plc (NASDAQ:BCYC)EntryPoint Capital LLC bought a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 43,873 shares of the company's stock, valued at approximately $March 26, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have assignMarch 26, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Reaches New 12-Month Low - What's Next?Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - Here's WhyMarch 25, 2025 | marketbeat.comPlatinum Investment Management Ltd. Buys 36,910 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Platinum Investment Management Ltd. grew its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 309,059 shares of the company's stock afMarch 20, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Reaches New 1-Year Low - Should You Sell?Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Here's WhyMarch 18, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 6% - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Trading 6% Higher - What's Next?March 13, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday.March 12, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - What's Next?Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - What's Next?March 10, 2025 | marketbeat.comCandriam S.C.A. Raises Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Candriam S.C.A. boosted its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,087,876 shares of the company'sMarch 7, 2025 | marketbeat.comB. Riley Predicts Reduced Earnings for Bicycle TherapeuticsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - B. Riley reduced their FY2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a research note issued on Monday, March 3rd. B. Riley analyst K. Patel now forecasts that the company will post earnings of ($3.75) per share for theMarch 6, 2025 | marketbeat.comAnalysts Set Expectations for BCYC Q1 EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.87March 4, 2025 | marketbeat.comPrincipal Financial Group Inc. Lowers Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Principal Financial Group Inc. decreased its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 406,470 shares of thMarch 4, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Should You Sell?Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 52-Week Low - Here's WhyMarch 3, 2025 | marketbeat.comBrokers Offer Predictions for BCYC FY2025 EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a research note issued on Wednesday, February 26th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn (March 1, 2025 | marketbeat.comHC Wainwright Issues Negative Estimate for BCYC EarningsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Bicycle Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per shMarch 1, 2025 | marketbeat.comQ1 EPS Estimate for Bicycle Therapeutics Reduced by AnalystBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Research analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for shares of Bicycle Therapeutics in a report released on Tuesday, February 25th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earniMarch 1, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to theMarch 1, 2025 | marketbeat.comFY2026 Earnings Estimate for BCYC Issued By Leerink PartnrsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Research analysts at Leerink Partnrs issued their FY2026 earnings estimates for Bicycle Therapeutics in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst J. Chang anticipates that the companyFebruary 28, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)February 27, 2025 | markets.businessinsider.comBicycle Therapeutics (BCYC) Receives a Hold from Morgan StanleyFebruary 27, 2025 | markets.businessinsider.comBicycle Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 26, 2025 | finance.yahoo.comBicycle Therapeutics price target lowered to $42 from $53 at JefferiesFebruary 26, 2025 | markets.businessinsider.comBarclays Remains a Buy on Bicycle Therapeutics (BCYC)February 26, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSBicycle Therapeutics (NASDAQ:BCYC - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.16) EPS.February 26, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $30.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday.February 26, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday.February 26, 2025 | marketbeat.comBicycle Therapeutics reports Q4 EPS (75c), consensus (85c)February 25, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)February 25, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Hits New 12-Month Low - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Hits New 12-Month Low - What's Next?February 25, 2025 | marketbeat.comBicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 25, 2025 | finanznachrichten.deBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 25, 2025 | businesswire.comBicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling RecentlyFebruary 14, 2025 | msn.comBicycle Therapeutics (BCYC) Expected to Announce Quarterly Earnings on TuesdayBicycle Therapeutics (NASDAQ:BCYC) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports.February 11, 2025 | marketbeat.com Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Media Mentions By Week BCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCYC News Sentiment▼0.910.72▲Average Medical News Sentiment BCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCYC Articles This Week▼55▲BCYC Articles Average Week Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Twist Bioscience News Today Metsera News Today Vericel News Today Schrödinger News Today Denali Therapeutics News Today Mirum Pharmaceuticals News Today Tarsus Pharmaceuticals News Today Beam Therapeutics News Today NewAmsterdam Pharma News Today Kymera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCYC) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCYC Stock Free BCYC Stock Alerts